Peterson, Erik R.
Sajjakulnukit, Peter
Scott, Andrew J.
Heaslip, Caleb
Andren, Anthony
Wilder-Romans, Kari
Zhou, Weihua
Palavalasa, Sravya
Korimerla, Navyateja
Lin, Angelica
O’Brien, Alexandra
Kothari, Ayesha
Zhao, Zitong
Zhang, Li
Morgan, Meredith A.
Venneti, Sriram
Koschmann, Carl
Jabado, Nada
Lyssiotis, Costas A.
Castro, Maria G.
Wahl, Daniel R.
Funding for this research was provided by:
ChadTough Defeat DIPG Foundation
Alex's Lemonade Stand Foundation for Childhood Cancer
Rogel Cancer Center, University of Michigan
National Cancer Institute (5T32CA140044-13, F32CA260735, K08CA234416)
Medical School, University of Michigan (U083054)
Sontag Foundation
National Institutes of Health (R01CA240515)
Pediatric Brain Tumor Foundation
Leah's Happy Hearts
Ian's Friends Foundation
Smiles for Sophie Forever Foundation
Department of Neurosurgery, University of Michigan, United States
National Institute of Neurological Disorders and Stroke (R21NS123879-01)
Forbes Institute for Cancer Discovery
Damon Runyon Cancer Research Foundation
Ivy Glioblastoma Foundation
Article History
Received: 1 September 2023
Accepted: 21 March 2024
First Online: 9 April 2024
Declarations
:
: Animal studies were conducted according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Michigan (approved protocol: PRO00010680). Publicly available, pre-published mRNA-seq Z-score expression and patient survival data from Mackay et al. (2017) was obtained using PedcBioPortal (Children’s Hospital of Philadelphia Research Initiative) [CitationRef removed, CitationRef removed, CitationRef removed].
: Not applicable.
: CAL is a member of the Editorial Board of Cancer & Metabolism, and has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-Knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach (US patent 2015126580-A1, 05/07/2015; US patent 20190136238, 05/09/2019; international patent WO2013177426-A2, 04/23/2015). DRW has received consulting fees from Agios Pharmaceuticals and Innocrin Pharmaceuticals and is an inventor on patents pertaining to the treatment of patients with brain tumors (U.S. Provisional Patent Application 63/416,146, U.S. Provisional Patent Application 62/744,342, U.S. Provisional Patent Applicant 62 /724,337).